Lassa Virus News and Research

RSS

Lassa virus or Lassa viral haemorrhagic fever is an acute illness of 1-4 weeks duration that occurs in West Africa. Though first described in the 1950s, the virus causing the disease was not identified until 1969. The virus is a single-stranded RNA virus belonging to the virus family Arenaviridae. Lassa fever is known to be endemic in Guinea (Conakry), Liberia, Sierra Leone and parts of Nigeria, but probably exists in other West African countries as well.

Neuroscientist, researchers receive Vilcek Prize in Biomedical Science

The Vilcek Foundation is pleased to name Thomas M. Jessell as the winner of the 2014 Vilcek Prize in Biomedical Science. Awarded annually, the Vilcek Prizes honor the contributions of immigrants to the American arts and sciences, and include $100,000 cash awards.

30 Jan 2014

Ebola, Marburg and Lassa viruses must be designated as emerging diagnoses

The Ebola, Marburg and Lassa viruses are commonly referred to as emerging diseases, but leading scientists say these life-threatening viruses have been around for centuries.

15 Nov 2012

Bas-Congo virus associated with acute hemorrhagic fever in Africa

An isolated outbreak of a deadly disease known as acute hemorrhagic fever, which killed two people and left one gravely ill in the Democratic Republic of Congo in the summer of 2009, was probably caused by a novel virus scientists have never seen before.

28 Sep 2012

Scientists solve structure of key protein from Lassa virus

Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.

18 Nov 2010

NIH awards Corgenix Medical $600,000 grant to develop diagnostic tests for Ebola and Marburg virus

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, including innovative products for emerging pathogens and lethal viruses, today announced a major extension of the collaborative effort to combat important viral diseases.

15 Apr 2010

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

10 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Discovery of new arenavirus associated with hemorrhagic fever – first identified in nearly four decades

Scientists at Columbia University's Mailman School of Public Health, the South African National Institute for Communicable Diseases of National Health Laboratory Service (NICD-NHLS), the U.S. Centers for Disease Control and Prevention, and Roche's 454 Life Sciences Corporation have discovered the new virus responsible for a highly fatal hemorrhagic fever outbreak in Zambia and South Africa in late 2008.

2 Jun 2009